FAQ: Humacyte's $60 Million Registered Direct Offering and Company Overview
Summary
Humacyte, Inc. has announced a $60 million registered direct offering of common stock and warrants to institutional investors, with closing expected around October 8, 2025. This funding supports the company's development of universally implantable bioengineered human tissues, including their FDA-approved acellular tissue engineered vessel for vascular trauma.
What is the main announcement from Humacyte?
Humacyte has entered into a securities purchase agreement for an oversubscribed registered direct offering totaling approximately $60 million, issuing 28,436,018 shares of common stock and accompanying warrants at $2.11 per unit.
How much funding is Humacyte raising and what are the terms?
The company is raising $60 million in gross proceeds before fees and expenses by issuing shares and warrants at $2.11 per unit. The warrants become exercisable 180 days after issuance, carry a $2.11 exercise price, and expire April 7, 2031.
When is the offering expected to close?
The closing of the registered direct offering is anticipated to occur on or about October 8, 2025.
What does Humacyte develop as a biotechnology company?
Humacyte develops universally implantable bioengineered human tissues, advanced tissue constructs, and organ systems designed to improve patient lives and transform medical practice, including acellular tissues to treat various diseases, injuries, and chronic conditions.
What regulatory approvals has Humacyte received for its products?
The FDA approved Humacyte’s Biologics License Application for the acellular tissue engineered vessel (ATEV) in extremity vascular trauma in December 2024. The ATEV has also received multiple RMAT designations, Fast Track designation, and priority designation from the U.S. Secretary of Defense.
What are the current clinical applications for Humacyte’s ATEV technology?
ATEVs are in late-stage clinical trials for arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD), with preclinical development underway for coronary artery bypass grafts, pediatric heart surgery, type 1 diabetes treatment, and other novel cell and tissue applications.
Who is managing the registered direct offering?
D. Boral Capital LLC is acting as the exclusive placement agent for the $60 million registered direct offering.
Where can I find more information about Humacyte and this announcement?
For more company information, visit https://humacyte.com/. To view the full press release, visit https://ibn.fm/XxOpk.
Why is this funding important for Humacyte’s operations?
This $60 million offering provides capital to support Humacyte’s commercial-stage biotechnology platform development, including advancing their universally implantable bioengineered human tissues through clinical trials and regulatory processes.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 253052